Affymax, Inc. AFFY

AFFY Company Overview

Affymax, Inc. (NASDAQ: AFFY) was a biopharmaceutical company focused on the development and commercialization of therapies for serious and chronic medical conditions, particularly in nephrology and anemia treatment. The company was best known for developing peginesatide, a synthetic erythropoiesis-stimulating agent marketed under the brand name Omontys for the treatment of anemia associated with chronic kidney disease in dialysis patients. Affymax operated within the biotechnology and specialty pharmaceutical industries, with its primary revenue prospects historically tied to licensing agreements, commercialization milestones, and potential product sales associated with Omontys.

Affymax was founded in 2001 following the acquisition of the original Affymax research assets from GlaxoSmithKline plc. The company pursued a model centered on drug discovery partnerships and targeted therapeutic development. Its strategic positioning was based on the differentiated synthetic peptide technology underlying peginesatide, which aimed to offer dosing convenience compared with traditional biologic erythropoiesis-stimulating agents. However, following safety concerns and a nationwide recall of Omontys in 2013, Affymax significantly reduced operations and subsequently entered restructuring activities. Public disclosures after this period indicate limited operating activity, and later-stage operational details are inconclusive based on available public sources.